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erythropoietin treatment, while in the first 12 months after the bid 3647 patients, 
resulting in a 12.5% decline. In the 12 months before biosimilar bid 13974 patients 
received colony-stimulating factor treatment, while in the first 12 months after the 
bid 13352 patients, resulting in a 4.5% decline. ConClusions: The analyses of the 
Hungarian price competition bid of biosimilar products showed a minimal decline 
in the number of patients under treatment by both colony-stimulating factor and 
erythropoietin products while the health insurance reimbursement of these drugs 
significantly decreased.
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objeCtives: Prior authorization (PA) restrictions have been implemented by US 
health plans in an effort to ensure safety, manage appropriate utilization and control 
costs. A review of published peer-reviewed literature was conducted to evaluate 
the impact of such PA restrictions on resource utilization and costs. Methods: A 
targeted review of literature was conducted in Medline from 2009 onwards using 
search terms including “prior authorization”, “resource”, “use”, “utilization”, “cost”, 
“impact”, “economic”. Review articles, non-English language studies, non-US stud-
ies, kins, and studies evaluating the effectiveness of formulary policies of which PA 
may be a component were excluded. Impact of PA policies on health care utilization 
and costs was qualitatively assessed. Results: Fourteen studies were identified 
which met our inclusion criteria. Majority (57%) of the studies were conducted on 
Medicaid plans (Medicaid: 8, commercial: 4, Medicare: 1, not clear: 1). Majority (57%) 
of studies evaluated the impact of mental health medications (anti-convulsants, 
anti-depressants bipolar medications, antipsychotics), two studies were conducted 
on anti-diabetics, one on a multiple sclerosis drug, one for a lipid-lowering drug, 
one on an anti-hypertensive and one on a vaccine. Four studies were industry-
sponsored. 12 studies were retrospective data analyses and only 2 studies were 
decision-analytic models. Overall, the trend showed that PA restrictions were effec-
tive in reducing pharmacy utilization and health care costs, but few studies also 
raised concerns on patient safety and quality of care outcomes due to PA poli-
cies. ConClusions: Although PA restrictions may result in cost-savings, patient 
safety and quality of life concerns must also be evaluated while imposing these 
restrictions. Rigorously designed studies including assesment of PA administration 
costs as well as indirect costs due to lost productivity should be conducted to better 
assess the overall economic impact of such restrictions.
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objeCtives: The objective is to test the hypothesis whether NICE recommendations 
on the use of a new drug affect recommendations from other bodies in countries 
outside England and Wales. To our knowledge, this is the first attempt to approach 
this topic quantitatively. Therefore, a sub-objective is to determine the feasibility 
of gathering a high quality database with sufficient number of observations to 
test our hypothesis. Methods: A basket of 29 drug/indication pairs and a group 
of 15 countries were included (Australia, Canada, Denmark, France, Italy, Korea, 
The Netherlands, New Zealand, Poland, Portugal, Spain, Bosnia, Ecuador, Egypt and 
Ghana). Information regarding NICE HTA recommendations was extracted from 
NICE’s website and HTAinSite. com. Moreover, an online-survey of key opinion lead-
ers was carried out to collect information regarding the HTA decision in 10 coun-
tries. For the remaining five countries, we used the information from their official 
webpages. A descriptive analysis was conducted, including an examination of the 
position of each decision of NICE in comparison with that of other HTA agencies in 
the timeline of decision making about the 29 medicines. Results: There is a lack 
of comparability between the publically available information. The findings suggest 
that after the publication of a NICE appraisal there is a higher probability that an 
HTA is undertaken for the same drug in other countries. Furthermore, when NICE 
has published a negative decision, the tendency of not recommending the drug by 
another HTA body is much larger after than before NICE’s decision. ConClusions: 
Issues encountered in the collection of information made it difficult to quantify the 
effect of NICE recommendations on HTA decisions in other countries. The results 
suggest that the selected agencies are considering NICE decisions as a factor for 
rejecting or restricting the use of drugs which in other case would be recommended 
or reimbursed.
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objeCtives: Little information is available on complication-related resource utiliza-
tion and costs over time in patients with complex abdominal wall reconstruction. 
Under pay-for-performance requirements financial decision-makers need better 
information to allocate health care resources and budget dollars. This analysis 
reports complication-related resource utilization and costs over time in a real-world 
patient population undergoing complex abdominal wall reconstruction. Methods: 
A cohort of patients with complex abdominal wall reconstructions during inpa-
tient stays between1/1/08 and 6/30/11 (Index event) were followed for 12 months. 
Related complications, returns for facility-based care and related costs were evalu-
ated for 30-60-90-365 days after discharge. Insurance claims from the Truven Health 
each country’s department of health. Countries were reviewed under a range of 
headings including: current delivery models in place, institutions responsible for 
delivery and organisation of reimbursement system, incentive structures in place, 
basic bundle of health care covered, additional options for coverage, disease-specific 
resource use and health outcomes, government contribution to cost of health care 
and overall health care expenditure. Results: Generally, the basic bundle of health 
care across countries with Universal entitlement ensures comprehensive medi-
cal care for everyone including GP services, access to tertiary care, post-natal care 
and medications. Co-payments, excess payments and retention fees apply in some 
countries dependent upon the Universal delivery model in place. ConClusions: 
This review presents characteristics of Universal health care delivery systems across 
Europe. Basic bundles of health care provision and organisation of reimbursement 
across delivery models have been outlined, thus providing further clarity on the 
characteristics of and variation across Universal health care models.
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objeCtives: By 2013 all European Union (EU) member states were recommended 
to elaborate and adopt a national strategy for rare diseases. This study provides 
insights into the national rare disease strategies, in particular about the status of the 
programmes, recent developments, and the congruencies and differences between 
the programmes regarding market access. Methods: A literature and Internet 
search was performed to identify national strategies for rare diseases published by 
EU member states. Both policies and recent orphan drug introductions have been 
analysed to compare the rare disease strategies. Results: All member states had a 
variety of approaches already in place before developing a national strategy. France 
is the frontrunner in implementing rare disease policies as well as the member 
state with the highest number of marketed orphan drugs. Over the past five years, 
most member states finalised their national plans with a peak in publications late 
2013. Plans include similar methods on increasing patient access such as off-label 
use, compassionate drug use and utilising cross-border health care. Member states 
with a decentralised market access model (e.g., Spain and Italy) commonly use 
national funds and decision-making to provide equity in treatment levels across 
the nation for rare diseases. There are few orphan drug specific pricing policies; 
however special reimbursement criteria are common especially in countries with 
cost-effectiveness criteria. ConClusions: Increasing patient access to orphan 
drugs has been a focus point in the national plans for rare diseases. Congruencies 
in methods will aid the EU’s ambition to align policies at European level. However 
the implementation phase has only recently been initiated for most plans and actual 
policies are yet to be developed. As member states such as France are introducing 
cost-effectiveness criteria in their health technology assessments, one can expect 
that tailored criteria need to be developed for orphan drug assessments.
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objeCtives: Hospitals are important cost elements of the Hungarian health care 
system. During the past decade, several health care reform affected the number 
of hospital beds in Hungary. The aim of our research is to analyse the efficiency 
of the Hungarian acute inpatient-care system. Methods: Data derived from 
the Hungarian nationwide health insurance database. We analyzed the techni-
cal- (TE) and scale efficiency (SE) of the Hungarian acute inpatient-care system 
(2003, 2006, 2010). The number of hospitals included into the study was 133 in 
2003,125 in 2006 and 93 in 2010. We chose four inputs and two outputs: the number 
of active hospital beds, the number of discharged patients, the number of one-
day cases, completed days of nursing (inputs), average length of stay, DRG cost 
weights (outputs). The method we used for our calculations was Data Envelopment 
Analysis. Results: In 2003 both the technical and scale efficiency were high 
(TE: 96.9%; SE: 92.9%). To 2006 the situation deteriorated by some degree (TE: 96.6%; 
SE: 80.3%). By 2010 technical efficiency still did not show improvement (TE: 94.0%), 
but scale efficiency increased (SE: 88.2%). Usually the hospitals with higher number 
of beds are more efficient than the smaller units. ConClusions: The effects of the 
performance volume limit did not improve the two values; however, the capacity 
decrease of 2007 did improve the scale efficiency to some extent. The Hungarian 
health care system needs to reduce the numbers of hospitals and rethink their 
functions, but needs to improve the size of them.
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objeCtives: The aim of our study is to analyse the biosimilar bids of the Hungarian 
National Health Insurance Fund Administration in case of colony-stimulating factor 
and erythropoietin products. Methods: Data derived from the nationwide phar-
maceutical database of Hungarian National Health Insurance Fund Administration. 
We analysed how the number of patients treated by colony-stimulating fac-
tor and erythropoietin products changed before (01.07.2011.-30.06.2012.) and 
after (01.07.2012.-30.06.2013.) the first biosimilar bid performed in March 2012 in 
Hungary. Results: In the 12 months before biosimilar bid 4167 patients received 
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objeCtives: Throughout Europe, economic conditions are forcing health care sys-
tems to reduce costs. One primary driver of health care costs is hospital length of 
stay (LOS). This study sought to determine which European countries have been 
most successful at reducing their average LOS for five inpatient admissions. This 
research also sought to quantify the potential savings for countries that have 
not been as successful in reducing their average LOS if they can align with their 
peers. Methods: A review of hospital LOS and cost per day of hospital stay data 
was conducted in five European countries (France, Germany, Italy, Spain and the 
United Kingdom), utilizing data published by the World Health Organization (WHO). 
Additionally, hospital payment systems were assessed in each country through 
published research to understand systemic motivations of health care providers 
with regards to LOS. Results: Substantial variability exists in average LOS for the 
studied admissions. The greatest variability was in breast cancer, with average stays 
ranging from 4.36 days in the UK to 11.01 days in Germany. The average LOS for three 
admissions (single spontaneous delivery, cataracts, and pneumonia) are relatively 
similar across countries. However, the average LOS in Germany for malignant neo-
plasm of the breast and acute myocardial infarction are significantly higher than 
the other four countries. There is little variability, however, in average costs per 
bed-day in the target countries. A review of payment mechanisms for inpatient 
stays revealed that hospitals are financially incentivized to minimize LOS in all five 
countries. ConClusions: Additional research is needed to understand the reason 
for the discrepancy between German stays and the other four countries. While there 
are many potential reasons for the differences, should Germany align their average 
LOS for malignant neoplasm of the breast and acute myocardial infarction with the 
other four countries, they could save € 744 million per year.
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objeCtives: The pharmaceutical industry is in the center of political debate due 
to their high profitability. In this study, we argue that abnormal profitability in the 
pharmaceutical industry is a kind of optical illusion created by accounting stand-
ards and their influence on reported accounting profit and book equity – the two 
components of ROE. The internationally accepted accounting frameworks either 
do not permit capitalizing R&D investments as U. S. GAAP or limit capitalizing R&D 
investments as International Financial Reporting Standards (IFRS) applicable in 
the E. U. and most countries. This treatment understates assets and equity, and 
can overstate reported profit because relevant cost components (amortization of 
R&D) are not deducted from revenues they generate. We empirically aim to esti-
mate the magnitude of this accounting bias. Methods: Based on international 
financial data of 413 pharmaceutical firms between 1972 and 2012, we assessed 
the “true” profitability of pharmaceutical firms by capitalizing R&D and amortizing 
it over the shelf-life of developed products. We use three amortization approaches 
(linear amortization, declining-balance amortization and amortization based 
on the empirical amortization rates). Results: Corrected profit and equity 
figures lead to substantially lower long-term profitability of pharmaceutical 
firms. Over the three proposed amortization approaches, the corrected ROE of 
14.1% is comparable to profitability reported by U. S. firms from other indus-
tries (ROE = 11.1%). Non-U. S. pharmaceutical firms also have an adjusted ROE 
that is comparable to firms from other industries (7.6% pharma vs. 9.6% non-
pharma). ConClusions: The policy implication of our study is that price regula-
tion or rate of return regulation in the pharmaceutical market should be reviewed 
and applied with caution when it is solely motivated by the allegedly high profit-
ability of the industry. This is especially true since such a policy also impedes 
R&D investments and innovation in the long run because profits serve as a major 
source of R&D investments.
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objeCtives: Specialty drugs are often many times more expensive than traditional 
drugs, raising questions of affordability, and whether their clinical benefits are 
worth their added costs. The objective of this study was to consider new molecular 
entities (NME) (i. e., drugs that had not previously been approved by the FDA or 
marketed in the US) approved by the FDA from 1999 through 2011 to compare the 
value of specialty and traditional drugs. Methods: We searched the FDA website 
to identify all NMEs approved from 1999 through 2011. We identified published esti-
mates of additional health gains (measured in quality adjusted life years (QALYs)) 
and costs (drug costs, hospitalization costs, etc) associated with specialty drugs 
compared to existing standard of care at their time of approval, and compared 
findings with traditional drugs. We compared incremental QALY gains, incremen-
tal costs, and the incremental cost-effectiveness ratio, for specialty vs. traditional 
drugs using a Mann Whitney U test. Results: We identified relevant estimates 
of additional health gains and costs for 101 (36%) of NMEs, including 59 specialty 
drugs. We found specialty drugs offered greater QALY gains than traditional drugs 
(0.19 vs. 0.01, p< 0.01), but were associated with greater additional costs ($10,460 
vs. $906, p< 0.01). We found the cost-effectiveness of the different drug types to be 
broadly similar (p= 0.58). ConClusions: This research suggests specialty drugs 
may offer greater health benefits over existing care than traditional drugs, and 
despite specialty drugs being associated with greater costs, specialty and traditional 
drugs were comparable in terms of cost-effectiveness. As payers search for ways to 
control health care costs it is important to recognize the relative benefits as well as 
the costs of specialty drugs, and to mitigate inappropriate use and waste to ensure 
that effective treatments are affordable to patients.
Analytics MarketScan® database, inpatient costs from the Healthcare Cost and 
Utilization Project (HCUP) and costs reported for Ambulatory Patient Classifications 
(APC) were used to estimate costs from the hospital perspective. Results: 13,463 
patients were evaluated. Rates of patients experiencing any complication were 
17.3% within 30 days, 11.0% within 31-60 days, 8.1% within 61-90 days, and 21.4% 
within 91 days – 12 months. In total, 37.8% of patients experienced a complication 
over 12 months. The most frequent complications over 12 months were infection 
(16.6%), bowel obstruction/ other GI complication (12.6%), skin/connective tissue-
related complications (10.7%), and wound complications (8.1%). Complication-
related cost over time followed a similar trend; average 12 month cost for patients 
experiencing an infection was $20,679, $21,558 for bowel-related complications, 
$14,950 for skin/ connective tissue related complications and $19,230 for wound 
complications. The index event average length of stay for patients with no complica-
tions and patients with complications was 3.9 (sd 4.4) and 17.0 (sd 19.6), respectively; 
p< 0.0001. ConClusions: Health care resource utilization, costs and complications 
for complex abdominal wall reconstruction patients increase over time. Resource 
utilization is exacerbated when complications occur. Further study may be required 
to validate these findings.
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Many people in Ireland suffer from chronic diseases including AF, diabetes, COPD 
and asthma. With the prevalence of these conditions expected to rise, general 
wellbeing and quality-of-life will be increasingly affected. Chronic conditions also 
account for most of the health care resources used, and represent a significant 
economic burden for Ireland in the future. objeCtives: Estimate the number of 
preventable disease associated events and costs associated with poor management 
of patients with AF, diabetes, COPD and asthma. Methods: For each province, 
calculate the number of patients diagnosed with AF, diabetes, COPD or asthma, 
based on disease prevalence and 2011 Census data. Estimate the number of patients 
not achieving target management of their condition and the associated number of 
preventable events and total costs, using publically available information. Results: 
Of the approximately 59,647 patients diagnosed with AF in Ireland, 23,561 patients 
are not receiving appropriate anticoagulation treatment. This results in 531 patients 
experiencing an avoidable stroke each year, costing the health care system around 
€ 9.3m. Amongst the 238,589 patients diagnosed with type 2 diabetes, 77% will not 
achieve a target HbA1c of 6.5% or less, resulting in an expense of € 886m and 12,493 
avoidable deaths each year. In addition, 30% of diagnosed COPD patients, and as 
many as 60% of asthma patients, are not managing their condition effectively, 
costing the Irish health care system € 899m per year in hospital admission costs 
alone. ConClusions: Much of the chronic disease burden is caused by preventable 
risk factors. This is intended as a key policy lever, to elevate chronic diseases on the 
health agenda of key policymakers, providing them with better evidence about risk 
factor control, and persuading them of the need for health systems change. Unless 
steps are taken now to effectively deal with chronic diseases, Ireland is headed for 
serious financial and quality-of-life crises.
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objeCtives: As health care costs continue to rise, employers seek options to improve 
the health and wellness of their employees. This study examined the practices of 
employers that are actively engaged in promoting employee health. Methods: 
A study of 18 employers who applied for the Working Well award provided by the 
Louisiana Business Group on Health in 2013, recognizing employers who are exem-
plar in their employee health and wellness activities. Applicants completed a survey 
detailing business policies and programs intended to promote wellness. De-identified 
data derive from 2013 applications. Results: Over half of the companies had fewer 
than 500 employees (55.6%), 4 had more than 2000. Health plan coverage was fully (8; 
44.4%) or self (7; 38.9%) funded. Almost half implemented wellness programs within 
the last 3 years (44.4%), whereas 4 (22.2%) had programs more than 10 years; all were 
company funded. Annual spend on wellness was split across participating employ-
ers with 55.6% spending < $50,000 and the rest > $50,000 (8; 44.4%). Rationale most 
cited for programs: improve employee wellbeing (18; 100%), contain health care costs 
(17; 94.4%), increase productivity (13; 72.2%), and reduce absenteeism (12; 66.7%). 
Most employers incentivized program participation (16; 88.9%) through premium 
reductions (8; 44.4%), cash (8; 44.4%), or PTO (3; 16.7%). Information most reported 
to help with wellness planning were health risk assessments (HRAs) (15; 83.3%), 
health care claims and utilization (14; 77.8%), and worker’s compensation claims 
(8; 44.4%). ConClusions: In the US, employers are responsible for a significant por-
tion of health care spend. Though a small self-selected sample, this analysis reveals 
that employers actively engaging their employees, using prevention and incentives 
to promote wellness are a more recent occurrence. The trend suggests increasing 
awareness that efforts to improve employee health and wellness can help attract 
and retain staff, as well as potentially reducing health care costs.
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